TP53 and B-cell chronic lymphocytic leukemia: In a group of patients with CLL (young, fit with mutated IGHV, without TP53 mutations or deletions in chromosomes 11 or 17), a defined course of therapy with fludarabine, cyclophosphamide, and rituximab has been shown to be of great benefit and many patients achieve durable remissions [28, 34–43].